Cargando…
Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study
INTRODUCTION: Neuropathic pain is a widespread problem with a big impact on quality of life. The currently used drug regimens are often insufficiently effective or cause – sometimes unacceptable – side effects. Intravenous lidocaine could be an alternative treatment, by blocking spontaneous depolari...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624148/ https://www.ncbi.nlm.nih.gov/pubmed/36329833 http://dx.doi.org/10.2147/JPR.S379208 |
_version_ | 1784822169183715328 |
---|---|
author | Horvat, Sanja Staffhorst, Bas Cobben, Jan-Hein M G |
author_facet | Horvat, Sanja Staffhorst, Bas Cobben, Jan-Hein M G |
author_sort | Horvat, Sanja |
collection | PubMed |
description | INTRODUCTION: Neuropathic pain is a widespread problem with a big impact on quality of life. The currently used drug regimens are often insufficiently effective or cause – sometimes unacceptable – side effects. Intravenous lidocaine could be an alternative treatment, by blocking spontaneous depolarization and hyperexcitability in upregulated sodium channels in nociceptors. Research so far has shown varying results but the treatment protocols differed a lot and follow-up was usually short. In our hospital, lidocaine infusions have been applied for many years in a unique treatment protocol consisting of a relatively high dose of lidocaine (1000 mg) administered over 25 hours. Our aim is to share information on both the efficacy and safety of this treatment schedule. METHODS: We conducted a retrospective cohort study in all patients who received a lidocaine infusion between January 2014 and January 2018. The standard infusion protocol consists of a total of 1000 mg lidocaine administered intravenously during 25 hours (40 mg/hour). Pain diagnoses were stratified into 15 groups, in agreement with diagnoses used in daily practice. Effectiveness of the treatment was classified as effect or no effect based on the description found in the chart. RESULTS: We included 282 patients, with a median age of 58 years and 64% of whom were female. Patients with myofascial pain syndrome, peripheral (mono)neuropathy, small fiber neuropathy and vascular disease benefited most. Patients with cancer pain, postherpetic neuralgia, chemotherapy-induced neuropathy and radicular pain showed the least pain improvement. There were no serious adverse events. CONCLUSION: In selected patients, lidocaine infusions may be a safe and efficacious treatment for chronic neuropathic pain. More prospective research is needed to further determine the optimal dosing, duration and interval of lidocaine infusion therapy, and to better understand in which specific patient categories this treatment is most beneficial. |
format | Online Article Text |
id | pubmed-9624148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-96241482022-11-02 Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study Horvat, Sanja Staffhorst, Bas Cobben, Jan-Hein M G J Pain Res Original Research INTRODUCTION: Neuropathic pain is a widespread problem with a big impact on quality of life. The currently used drug regimens are often insufficiently effective or cause – sometimes unacceptable – side effects. Intravenous lidocaine could be an alternative treatment, by blocking spontaneous depolarization and hyperexcitability in upregulated sodium channels in nociceptors. Research so far has shown varying results but the treatment protocols differed a lot and follow-up was usually short. In our hospital, lidocaine infusions have been applied for many years in a unique treatment protocol consisting of a relatively high dose of lidocaine (1000 mg) administered over 25 hours. Our aim is to share information on both the efficacy and safety of this treatment schedule. METHODS: We conducted a retrospective cohort study in all patients who received a lidocaine infusion between January 2014 and January 2018. The standard infusion protocol consists of a total of 1000 mg lidocaine administered intravenously during 25 hours (40 mg/hour). Pain diagnoses were stratified into 15 groups, in agreement with diagnoses used in daily practice. Effectiveness of the treatment was classified as effect or no effect based on the description found in the chart. RESULTS: We included 282 patients, with a median age of 58 years and 64% of whom were female. Patients with myofascial pain syndrome, peripheral (mono)neuropathy, small fiber neuropathy and vascular disease benefited most. Patients with cancer pain, postherpetic neuralgia, chemotherapy-induced neuropathy and radicular pain showed the least pain improvement. There were no serious adverse events. CONCLUSION: In selected patients, lidocaine infusions may be a safe and efficacious treatment for chronic neuropathic pain. More prospective research is needed to further determine the optimal dosing, duration and interval of lidocaine infusion therapy, and to better understand in which specific patient categories this treatment is most beneficial. Dove 2022-10-28 /pmc/articles/PMC9624148/ /pubmed/36329833 http://dx.doi.org/10.2147/JPR.S379208 Text en © 2022 Horvat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Horvat, Sanja Staffhorst, Bas Cobben, Jan-Hein M G Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study |
title | Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study |
title_full | Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study |
title_fullStr | Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study |
title_full_unstemmed | Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study |
title_short | Intravenous Lidocaine for Treatment of Chronic Pain: A Retrospective Cohort Study |
title_sort | intravenous lidocaine for treatment of chronic pain: a retrospective cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624148/ https://www.ncbi.nlm.nih.gov/pubmed/36329833 http://dx.doi.org/10.2147/JPR.S379208 |
work_keys_str_mv | AT horvatsanja intravenouslidocainefortreatmentofchronicpainaretrospectivecohortstudy AT staffhorstbas intravenouslidocainefortreatmentofchronicpainaretrospectivecohortstudy AT cobbenjanheinmg intravenouslidocainefortreatmentofchronicpainaretrospectivecohortstudy |